INmune Bio Corporation - INMB Real Price to Acquire Entire Company

INmune Bio Corporation - graphic logo of issuer INMB

Investing in INmune Bio, Inc. (INMB) involves uncertainty regarding the outcomes of clinical trials for dementia and a continuous need for capital. This chart illustrating the price evolution shows that the Enterprise Value is 22.69. Currently, the firm is utilizing its existing reserves for research and development without active sales. Meanwhile, the business relies on partnerships with scientists to develop methods for combating oncology and Alzheimer's through the modulation of immune systems.

INMB (inmunebio.com) Total Company Value history from 11/23/2025 to 10/27/2026

INmune Bio, Inc. (INMB) - metric breakdowns and financial figures

- price and consensus price forecast:
Share Price INmune Bio Inc|INMB - Price Target Chart
- market capitalization data:
Market Valuation INmune Bio|INMB - Enterprise Value
- book capitalization data:
Net Assets per Single Share INmune Bio|INMB - Company Book Value|Market Capitalization to Net Assets inmunebio.com|INMB - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio INmune Bio, Inc.|INMB - Long-Term Debt to Capital|Short-Term Debt to Capital inmunebio.com|INMB - Company Debts|Debt to Net Assets Ratio INmune Bio
Comprehensive company analysis:INmune Bio Inc (INMB)
Original product of INmune Bio, Inc.

Enterprise value combines market capitalization and net debt, determining the actual cost of a full business buyout. This metric reflects the objective value of assets, stripped of liquidity influence. For INmune Bio, Inc. (INMB), the potential for pricing power in Alzheimer's therapy via the DN-TNF platform creates a foundation for growth in this valuation. An analysis of the business's fundamental value allows market optimism to be compared with actual costs. This chart confirms the company's investment attractiveness and resilience.

Competitor analysis for INmune Bio, Inc.

argenx N.V. - Business Value|BNTX: Total Company Value|ABVX - Real Price to Acquire Entire Company|ADMA Biologics (ADMA) - Enterprise Value|PTGX (protagonist-inc.com) - Total Company Value|Total Company Value Immunovant IMVT|Full Business Value Kiniksa Pharmaceuticals, Ltd.|Grifols Group (GRFS) - Enterprise Value|Value Adjusted for Debt and Cash Adaptive Biotechnologies Inc. (ADPT)|Enterprise Value CLDX (Celldex Therapeutics)|auriniapharma.com - Enterprise Value|Total Company Value BioCryst Pharmaceuticals (BCRX)|VERA: Value Adjusted for Debt and Cash|DNTH (Dianthus Pharma) - Total Company Value|Pharvaris Pharma (PHVS) - Real Price to Acquire Entire Company|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com (TRML)|Precigen (PGEN) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Pharming Group NV (PHAR)|Enterprise Value NKTR|Upstream Pharma - Company Buyout Price|ZBIO: Total Company Value|IMNM: Real Price to Acquire Entire Company|GOSS (Gossamer Bio) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|SEPN (Septerna Corp) - Real Price to Acquire Entire Company|Enterprise Value PVLA|Total Company Value Savara Inc. SVRA|Business Value rigel.com (RIGL)|ANAB: Enterprise Value|Total Enterprise Value Astria Therapeutics Inc ATXS|Enterprise Value ENGN (enGene Bio)|RAPT: Company Buyout Price|Total Company Value aerovatetx.com|ACRS (aclaristx.com) - Business Value|Total Company Value KYTX|Real Price to Acquire Entire Company Tiziana Life Sciences Ltd. (TLSA)|Real Price to Acquire Entire Company CABA|Enterprise Value VTYX (Ventyx Biosciences, Inc)|THTX - Total Company Value|Business Value avalotx.com AVTX|ELDN (Eledon Pharmaceuticals, Inc.) - Enterprise Value|Agenus, Inc. (AGEN) - Total Enterprise Value|Real Price to Acquire Entire Company Climb Bio, Inc. CLYM|Zura Bio Ltd (ZURA) - Value Adjusted for Debt and Cash|Enterprise Value aTyr Pharma, Inc.|Total Company Value Adagene Corp|IMA (ImageneBio Inc) - Enterprise Value|Company Buyout Price STTK (shattucklabs.com)|EQ: Total Company Value|CNTB - Total Enterprise Value|Real Price to Acquire Entire Company Immunic Inc (IMUX)|ATRA - Value Adjusted for Debt and Cash|inflarx.de - Enterprise Value|XFOR (X4 Pharmaceuticals Inc.) - Company Buyout Price|Total Company Value Adicet Bio Inc. (ACET)|Business Value Celularity Corp|Enterprise Value BRNS (Barinthus Biotherapeutics)|Real Price to Acquire Entire Company kezarlifesciences.com KZR|Real Price to Acquire Entire Company SABS|Company Buyout Price Akari Therapeutics PLC AKTX|Enterprise Value ENLV (Enlivex Therapeutics, Ltd.)|QTTB: Company Buyout Price|Total Company Value GeoVax Labs, Inc.|EDSA (edesabiotech.com) - Business Value|Total Company Value IBIO|Real Price to Acquire Entire Company Carisma Tx|Enterprise Value XTL Biopharmaceuticals, Ltd. (XTLB)|Total Company Value BOLT (boltbio.com)|HCW Biologics (HCWB) - Total Company Value|Full Business Value Aptevo Therapeutics, Inc. APVO|Enterprise Value AIM ImmunoTech Inc. (AIM)|ADTX - Value Adjusted for Debt and Cash|GRI: Enterprise Value|XRTX (XORTX Corp) - Enterprise Value|HIND - Total Company Value|Value Adjusted for Debt and Cash REVB|Total Company Value INDP (Indaptus Therapeutics, Inc.)|Real Price to Acquire Entire Company Scinai Immunotherapeutics Ltd (SCNI)|Enterprise Value CALI (CalciMedica)|AFMD - Enterprise Value|Real Price to Acquire Entire Company Allakos Therapeutics (ALLK)|HOOK - Value Adjusted for Debt and Cash|igmbio.com - Enterprise Value|ITOS (iTeos Therapeutics Inc) - Company Buyout Price|Total Company Value OCEA|Real Price to Acquire Entire Company TCBP|Total Company Value THRD (Third Harmonic Bio)